Assort Health: Goldman Sachs Just Led a $110 Million Bet

For the past two years, the AI startups grabbing headlines were the ones you could talk to. Chatbots, assistants, copilots. This week’s biggest funding rounds point somewhere quieter and arguably more consequential: AI that does not just talk to you, it decides things about you.

Two large rounds landed in the latest funding roundup, and both are bets on AI making the high-stakes decisions that humans used to make. One is in finance. One is in healthcare. Together they show where the smart money is actually going.

Here is what got funded and why it signals a shift.

Taktile’s $110 million

Taktile raised $110 million in a Series C round led by Goldman Sachs Alternatives, according to the June 24 funding roundup from Tech Startups. The company builds AI decision automation for financial institutions, handling underwriting, claims, fraud detection, onboarding and anti-money-laundering workflows.

Read that list of functions carefully. Underwriting decides who gets a loan and on what terms. Fraud detection decides which transactions get flagged. Onboarding and anti-money-laundering decide who gets to be a customer at all. These are the consequential, regulated decisions at the core of banking, and Taktile is building AI to automate them. Goldman Sachs leading the round is a strong signal from the heart of the financial establishment that this is where banking is headed.

Assort Health’s $120 million

The largest round in the roundup went to Assort Health, which raised $120 million in a Series C led by Menlo Ventures. Assort builds an AI agents platform for the patient journey, spanning scheduling, intake, referrals, document processing, medication refills, lab requests, payments and staff copilots.

Healthcare administration is notoriously broken, expensive and slow, and an enormous amount of it is repetitive decision-making and coordination, exactly the kind of work AI agents are being built to absorb. Assort is betting that the back office of medicine, the scheduling and intake and referral machinery that frustrates patients and burns out staff, can be run substantially by AI. At $120 million, investors are betting heavily that it can.

The pattern underneath both

Put Taktile and Assort side by side and the theme is clear. Both are building AI that takes over operational decision-making in a large, regulated, high-stakes industry. Neither is a consumer chatbot. Both are infrastructure for institutions, the systems that decide loans and claims, that schedule and route patients.

This fits the broader 2026 funding trend. Capital is concentrating into the infrastructure, workflow and decisioning layers that sit underneath AI adoption, rather than the consumer-facing applications that dominated the early hype, as Crunchbase has documented across recent weeks. Venture money is increasingly flowing to AI that runs the plumbing of regulated industries, not AI that entertains.

The rest of the week’s rounds

The decisioning theme ran through the smaller rounds too. xCures raised $46 million in a Series B led by Innovius Capital to convert fragmented medical records into structured, decision-ready clinical data. Runlayer raised $30 million in a Series A led by Felicis for agent governance and enterprise AI control. Coval raised $28 million in a Series A led by Norwest for voice AI testing infrastructure.

Notice what these have in common. Structured decision-ready data, agent governance, AI control layers, testing infrastructure. The market is funding the scaffolding required to deploy AI safely inside serious institutions. This is the unglamorous, essential work of making AI trustworthy enough to hand real decisions to, and it is where a lot of this week’s capital went.

Why discipline is back

The character of the funding market in 2026 is different from the anything-goes era of 2024. Startup funding is holding up, but the money is concentrated in fewer companies and sectors, and founders who show traction, cost discipline, real use cases and a believable path to market are the ones getting funded. The capital is there, but it is more selective, flowing to companies that can point to revenue and a clear application rather than a compelling demo.

That selectivity is part of why the rounds going to Taktile and Assort matter. These are not speculative bets on a futuristic concept. They are companies automating concrete, painful, expensive workflows in finance and healthcare, with the kind of real-world use case that attracts disciplined capital.

Why This Matters

The shift from conversational AI to decisioning AI is one of the most important and least-discussed trends in the industry. AI that chats is impressive but low-stakes. AI that decides who gets a loan, which transactions are fraud, or how a patient is scheduled and routed is operating in the core machinery of regulated industries, where the consequences of a wrong decision are real and the regulatory scrutiny is intense.

That these rounds are being led by names like Goldman Sachs and Menlo Ventures signals that the institutional establishment sees this transition as inevitable and wants to own the infrastructure that powers it. For workers in these industries, it is a preview of which functions AI is coming for next: not the creative or strategic work first, but the high-volume operational decision-making that quietly runs the system.

The NewsSparq Takeaway

Three things to hold onto.

One, the money moved from chat to decisions. The week’s biggest rounds, Taktile and Assort, are both AI that makes operational decisions in regulated industries, not consumer chatbots. That is where the capital is concentrating now.

Two, the establishment is leading. Goldman Sachs leading a fintech decisioning round and Menlo leading a healthcare AI round signal that institutional investors see this shift as the real opportunity, not a fringe bet.

Three, discipline defines the market. Funding is holding up but concentrating in companies with traction, real use cases and cost discipline. The era of funding demos is over. The era of funding workflows is here.

Goldman Sachs put $110 million behind AI deciding who banks trust. Menlo put $120 million behind AI running the patient journey. The headline AI was the one you could talk to. The AI that actually got funded this week is the one making the decisions, quietly, inside the systems that run your money and your medicine.

Sources: Tech Startups, Crunchbase News.

By The NewsSparq Editorial Desk

Goldman Sachs Just Led a $110 Million Bet on AI Running the Decisions Banks Used to Make